SCANA Corporation (SCG), The Southern Company (SO), NextEra Energy, Inc. (NEE): Will Natural Gas Kill Nuclear?

Page 1 of 2

Nuclear is the instant coffee of energy. It’s fast, accessible, and (as long as you’ve got a water boiler around) relatively cheap. But what’s here today may be gone tomorrow, according to a new report outlining the long-term outlook for nuclear generation. Let’s take a closer look to see if nuclear’s got what it takes to keep pouring profits into your portfolio.

The buzz
Nuclear energy
currently accounts for 101,000 MW of our nation’s electricity, about 19% of total generation. But nuclear’s heydays of new construction are well behind it. Plants are incredibly capital intensive, and new regulation keeps costs prohibitively high for most expansion opportunities.

Nuclear’s worst nightmare was, until recently, natural gas. But nat-gas prices are headed higher for 2013 and beyond, and nuclear may be back in business.

Although grandiose new projects are currently out of the question, construction and uprates will add an additional 19,000 MW of nuclear capacity over the next 25 years.

SCANA Corporation (NYSE:SCG)By 2020, TVA’s Watts Bar plant, SCANA Corporation (NYSE:SCG)‘s V.C. Summer station, and The Southern Company (NYSE:SO)‘s Vogtle project will contribute 5,500 MW of new nuclear. Just two weeks ago, NextEra Energy, Inc. (NYSE:NEE) announced that its newly completed five-year-uprate project added 500 MW of capacity, exceeding expectations by 25%.

Meanwhile, nuclear powerhouse Exelon Corporation (NYSE:EXC) will continue to generate around 20% of the nation’s nuclear energy with its 10 power plants and 17 reactors.

But natural gas prices dictate the degree to which nuclear demand heats up or cools down. A new EIA report outlines their expectation and three alternative scenarios for investors to swallow:


High gas prices could push up nuclear capacity by 26,000 MW. Alternatively, cheap natural gas would keep nuclear capacity constant over the next 25 years.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!